Cannvas MedTech (CSE:MTEC) (Frankfurt:3CM) (OTC:CANVF), a leader in digital cannabis education and a leading business technology company in the cannabis space, and Medical Marihuana Patient Relief Inc. (“MMPatient Relief”), a private late-stage Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license applicant, are pleased to announce the signing of a letter of intent (the “LOI”), to negotiate, in good faith, a joint marketing agreement whereby the two companies will work together to market and promote cannabis education. Cannvas will become the exclusive provider of cannabis information and education to the MM Patient Relief website and the MM Patient Relief product line will be integrated into the Cannvas Kiosk platform and featured in Cannvas Marché locations on digital marketing screens with fulfillment opportunities.

“We are building MM Patient Relief to be the most physician centric, data driven licensed producer to meet the needs of sophisticated clients who are looking for an effective alternative to pharmaceuticals,” said Alex Ciotoli, President, Medical Marihuana Patient Relief Inc. “Working with Cannvas enables us to have the latest education content which is a core component to meeting our objectives.”


“It’s encouraging to see an innovative Canadian cannabis company like MM Patient Relief recognize the value of unbiased cannabis education to become a valuable partner with the Cannvas.Me platform and help spread awareness on the potential health benefits the plant offers,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “Working closely with MMPatient Relief to create a joint marketing program highlighting both our strengths in the cannabis sector, we hope to leverage the Cannvas.Me platform to provide relevant and timely cannabis learning to potential and active MM Patient Relief clients focused on familiarizing themselves with its high quality products.”

MM Patient Relief lnc. will be using proprietary technology to increase the crop yield and quality of cannabis produced in a newly renovated stand-alone 10,000 sq.ft. building in Tecumseh, Ontario. It is planning to market to sophisticated customers seeking superior strains and alternatives to long-term pharmaceutical pain relief. MM Patient Relief is a l00% private and locally-owned business.

MM Patient Relief products will be featured in Cannvas Kiosks, a network of digital cannabis education kiosks powered by the Cannvas.Me platform and installed in high-traffic medical and retail areas. Products will also be placed in Cannvas Marché locations, a brick-and-mortar education hub with digital learning resources, on-site medical and educational staff and a fulfillment program. Each Marché also offers hands-on education sessions on a variety of cannabis-related topics with no pressure to purchase or consume.

About Medical Marihuana Patient Relief
Established in 2014, Medical Marihuana Patient Relief Inc. (MMPatient Relief) is a private, locally-owned business based in Tecumseh, Ontario. We are focused on creating high-quality, in-demand medical marihuana strains for pain, arthritis, and cancer. We use advanced cultivation methods that maximize production and have increased the number of yearly crop cycles from four to six. In the final stage of Health Canada MMPR / ACMPR (Access to Cannabis for Medical Purposes Regulation), our experienced team is finalizing construction of our state-of-the-art, stand-alone facility. Now, we’re inviting all Canadians to join us. Starting very soon, you’ll be able to invest in MMPatient Relief on FrontFundr.com, Canada’s largest investment crowdfunding.

For more information: www.mmpatientrelief.com.

About Cannvas MedTech Inc.
Cannvas MedTech is a leading business technology company in the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

For further information: www.cannvasmedtech.com; Media Inquiries: media@cannvasmedtech.com; Investor Relations, ir@cannvasmedtech.com, 1-800-489-0116

Related Links

https://cannvasmedtech.com

Click here to connect with Cannvas MedTech (CSE:MTEC) (Frankfurt:3CM) (OTC:CANVF) for an Investor Presentation. 

In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.

Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.

Keep reading... Show less

The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement

Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination

Keep reading... Show less

Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising

Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.

In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.

Keep reading... Show less

Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.

Keep reading... Show less